Co-delivery system to overcome mucosal barriers

Mucosal tissues are highly attractive access points for local and systemic drug delivery, but the mucus barrier remains a key limitation for many therapeutic formats. In particular, advanced nanoparticle systems often show strong functional potential yet insufficient transport through mucus. Solutions that improve mucosal penetration may broaden the applicability of next-generation drug delivery platforms and support more patient-friendly administration.
Life Sciences
Reference
b85197
IP right year
2026
IP status
Filed in 2026, PCT planned
Applicant

Challenge and innovation

Many nanoparticle drug carriers fail at mucosal interfaces because their transport relies on slow Brownian diffusion. In mucus, passive nanoparticles are hindered by steric constraints and adhesive interactions with the mucin network, leading to poor tissue access and rapid clearance by mucosal turnover. As a result, major administration routes such as oral or pulmonary delivery remain difficult for many nanomedicines.

This invention uses hydrodynamic coupling between active and passive particles directly in biological mucus to enhance transport of passive nanocarriers. Both particle types are co-embedded in a microparticle that protects the active component from premature activation and enables local co-release at the target mucosa. In proof-of-concept studies, passive particle mobility increased by more than tenfold, with improved penetration of passive particles into mucosal hydrogel barriers.